6287 search
Myriad Genetics
NASDAQ MYGN 28,12 US$ 46,92%
Logo

Two Picks in Small-Cap Pharma With Catalysts

Publié le 28 mai 2015

Pour voir l'article original, cliquez ici .

Les autres articles de la compagnie
Dozens of Genes in Breast Cancer Tests Have Tenuous Link to
Myriad Genetics Fights Off Threats From Rivals
Startup Pledges To Cut Cost Of Breast Cancer Genetic Testing
Cowen Thinks 3 Life Science Stocks Can Beat Earnings Estimat
Quest, Myriad Settle Patent Dispute on Breast Cancer Tests
Articles en illimité et contenus premium Je m'abonne
Editoriaux
et Nouvelles
Actions
Minières
Or et
Argent
Marchés La Cote
search 6287
search